Icon

ICLR

Market cap $14.1B

DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of our 2023 survey, while the second survey focused exclusively on trends in the rapidly growing Chinese biotech market. In total, both surveys captured insights from more than 260 biotech professionals and venture capital executives across the US, Europe, Asia-Pacific (APAC).

DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced results of its latest industry survey, examining the challenges clinical trial sites face during study startup. The findings underscore the need for a site-centric, collaborative approach to overcome bottlenecks and enhance trial activation timelines. The survey, conducted in June 2025 among just over 100 principal investigators and senior clinical trial site personnel, gathered per.

ICON Public Limited Company ( ICLR ) Jefferies London Healthcare Conference 2025 November 19, 2025 4:00 AM EST Company Participants Barry Balfe - CEO & Director Nigel Clerkin - Chief Financial Officer Conference Call Participants David Windley - Jefferies LLC, Research Division Presentation David Windley Jefferies LLC, Research Division All right. Good morning, everybody.

DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the Jefferies London Healthcare Conference.

Invesco International Small-Mid Company Fund outperformed most in the real estate and consumer staples sectors due to stock selection. The fund's underweight in real estate also added to relative return. The fund underperformed most in healthcare, information technology and materials due to stock selection.

ICON Public Limited Company (NASDAQ:ICLR ) Q3 2025 Earnings Call October 23, 2025 8:00 AM EDT Company Participants Kate Haven - Vice President of Investor Relations Steven Cutler Barry Balfe - CEO & Director Nigel Clerkin - Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Michael Cherny - Leerink Partners LLC, Research Division Justin Bowers - Deutsche Bank AG, Research Division Jailendra Singh - Truist Securities, Inc., Research Division Patrick Donnelly - Citigroup Inc., Research Division Jack Meehan - Nephron Research LLC Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division Charles Rhyee - TD Cowen, Research Division Michael Ryskin - BofA Securities, Research Division David Windley - Jefferies LLC, Research Division Kyle Crews - UBS Investment Bank, Research Division Luke Sergott - Barclays Bank PLC, Research Division Christine Rains - William Blair & Company L.L.C.

Icon PLC (ICLR) came out with quarterly earnings of $3.31 per share, beating the Zacks Consensus Estimate of $3.28 per share. This compares to earnings of $3.35 per share a year ago.

DUBLIN--(BUSINESS WIRE)--ICON Reports Third Quarter 2025 Results.

In H1 2025, ICON's net book-to-bill ratio dropped to its lowest value since at least 2016. However, this ratio could improve since macroeconomic uncertainty is vanishing. ICON has a repurchase program of $1,000 million underway, which could buy approximately 6.90% of the company's outstanding common shares. Despite the challenging times, ICON is a profitable firm, has low debt, and presents symptoms of undervaluation compared to other CRO companies.

Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.